



## Press Release

### Patent application for the production of monoclonal antibodies

#### Münster, Germany, July 2010:

Cilian AG today announced that it has applied for a patent for the production of antibodies in the proprietary expression platform of CILIAN (CIPEX). The application with number GB 1003701.8 and title "System for the heterologous expression of a monoclonal antibody (mAb) in a Ciliate host cell" addresses the use of antibodies obtained from Ciliates, specifically *Tetrahymena thermophila*, as therapeutic drug for cancer and other immunological diseases.

CILIAN has several other patents pending and granted applications that will continue to enhance the value of the company.

"This is a very important patent application for our Ciliate platform" said Dr. Marcus Hartmann, CSO of CILIAN. "Due to the unique features of the platform, antibodies produced in the CIPEX have an advantageous glycosylation pattern in comparison to conventional platforms." Remco Brandt, M.Sc., CEO of CILIAN added, "Since its inception, CILIAN has invested tremendous amounts of time and effort in the development of our platform. With this patent application, together with the granting of other patents the last years, Cilian has protected her main markets."

#### About Cilian AG

Founded in 2001 by Marcus Hartmann and partners, Cilian is an emerging biotechnology company developing and marketing a novel expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of enzymes and therapeutic proteins. Besides the expression platform Ciliates are also the basis for a new enzyme preparation, which will be developed by the company for the enzyme replacement therapy in the case of maldigestion. Leveraging the unique capabilities of the Ciliates, the Company aims to produce proteins at an unmatched quality and price, thereby fulfilling its mission to improve human health by facilitating access to biopharmaceuticals.

For further information, visit [www.cilian.com](http://www.cilian.com) or contact:

#### Cilian AG:

Marcus Hartmann, Ph.D. (CSO)

tel. +49 251 6 20 310

[hartmann@cilian.de](mailto:hartmann@cilian.de)